Cover Image
市場調查報告書

急性心臟衰竭的開發平台分析

Acute Heart Failure - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232836
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
急性心臟衰竭的開發平台分析 Acute Heart Failure - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 70 Pages
簡介

心臟衰竭是心臟無法送出身體所需的充分血液時的狀態。這個疾病的症狀是呼吸急促,四肢無力感,倦怠感,心率不規則又快的等。治療藥有ACE抑制劑,β- 阻斷劑,利尿劑等。

本報告提供急性心臟衰竭治療藥之開發情形相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

急性心臟衰竭概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

急性心臟衰竭:企業正在開發的治療藥

急性心臟衰竭:大學/機關研究中的治療藥

急性心臟衰竭:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

急性心臟衰竭:企業開發中的產品

急性心臟衰竭:大學/機關研究中的產品

急性心臟衰竭的治療藥的開發企業

  • Amgen Inc.
  • Angion Biomedica Corp.
  • Bayer AG
  • Lee's Pharmaceutical Holdings Limited
  • Novartis AG
  • Nyken BV
  • 小野藥品工業
  • PhaseBio Pharmaceuticals, Inc.
  • Trevena, Inc.

急性心臟衰竭:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ANG-4011
  • BR-5489
  • cenderitide
  • istaroxime
  • NYK-1112
  • omecamtiv mecarbil
  • ONO-4232
  • PB-1046
  • serelaxin
  • TRV-027
  • TRV-120023
  • ularitide

急性心臟衰竭:最近的開發平台趨勢

急性心臟衰竭:暫停中的計劃

急性心臟衰竭:開發中止的產品

急性心臟衰竭:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8234IDB

Summary

Global Markets Direct's, 'Acute Heart Failure - Pipeline Review, H2 2016', provides an overview of the Acute Heart Failure pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
  • The report reviews pipeline therapeutics for Acute Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Heart Failure therapeutics and enlists all their major and minor projects
  • The report assesses Acute Heart Failure therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Heart Failure

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Heart Failure Overview
  • Therapeutics Development
    • Pipeline Products for Acute Heart Failure - Overview
  • Acute Heart Failure - Therapeutics under Development by Companies
  • Acute Heart Failure - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acute Heart Failure - Products under Development by Companies
  • Acute Heart Failure - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Capricor Therapeutics, Inc.
    • Eli Lilly and Company
    • Lee's Pharmaceutical Holdings Limited
    • Novartis AG
    • Ono Pharmaceutical Co., Ltd.
    • PhaseBio Pharmaceuticals, Inc.
    • Trevena, Inc.
  • Acute Heart Failure - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cenderitide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • istaroxime - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omecamtiv mecarbil MR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-4232 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PB-1046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ruboxistaurin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • serelaxin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRV-120023 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ularitide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acute Heart Failure - Dormant Projects
  • Acute Heart Failure - Discontinued Products
  • Acute Heart Failure - Product Development Milestones
    • Featured News & Press Releases
      • Dec 11, 2015: Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure
      • May 22, 2015: Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure
      • Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide
      • Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation
      • May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure
      • May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure
      • Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome
      • Mar 25, 2014: FDA Staff Says Novartis' Serelaxin Shouldn't Be Approved
      • Jan 24, 2014: Novartis Europharm's Reasanz Receives CHMP Negative Opinion
      • Jan 24, 2014: Novartis to request re-examination of serelaxin in acute heart failure for conditional marketing authorization in EU
      • Dec 02, 2013: Paladin Announces Filing of New Drug Submission for RLX030 (Serelaxin)
      • Sep 03, 2013: Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
      • Sep 02, 2013: Novartis' serelaxin improved symptoms and mortality across multiple subgroups of patients with acute heart failure
      • Jun 21, 2013: Novartis's Serelaxin Receives FDA Breakthrough Therapy Designation For Acute Heart Failure
      • Mar 18, 2013: Cytokinetics Announces Update To Heart Failure Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Heart Failure, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Acute Heart Failure - Pipeline by Amgen Inc., H2 2016
  • Acute Heart Failure - Pipeline by Capricor Therapeutics, Inc., H2 2016
  • Acute Heart Failure - Pipeline by Eli Lilly and Company, H2 2016
  • Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Acute Heart Failure - Pipeline by Novartis AG, H2 2016
  • Acute Heart Failure - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016
  • Acute Heart Failure - Pipeline by Trevena, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acute Heart Failure - Dormant Projects, H2 2016
  • Acute Heart Failure - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Acute Heart Failure, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top